Key Highlights

  • Microba has secured firm commitments for a $2.025 million placement at $0.04 per share, in two tranches.
  • Core testing revenue was $2.57 million in Q1 FY27, up 31%, while total revenue of $3.44 million was down 4%.
  • Annualised cash operating costs are about $5 million lower than FY26, with a further $3 million of reductions planned.
  • Cash was $3.87 million at 30 September 2026, with a net operating cash outflow of $3.80 million for the quarter.

Microba Life Sciences Limited (ASX:MAP) announced on 20 October 2026 that it had received firm commitments to raise $2.025 million before costs, alongside its Q1 FY27 quarterly activities report and Appendix 4C. The two releases cover the placement terms, a cost reduction programme, leadership and board changes, a planned sale process for a supplements business and trading results for the September quarter.

Placement terms

The placement comprises 50,625,000 new shares at $0.04 each, a 9.1% discount to the last close of $0.044 on 19 October and a 13.0% discount to the 10-day volume weighted average price of $0.046. Substantial shareholder Sonic Healthcare is participating alongside Perennial Partners and Thorney. Tranche 1 raises $1.025 million through 25,625,000 shares under existing placement capacity, with settlement expected on 26 October 2026. Tranche 2 raises $1.0 million through 25,000,000 shares and requires shareholder approval at a general meeting expected in December, as well as approvals for the proposed merger with Genetic Signatures Limited (ASX:GSS). If those conditions are not met, Tranche 2 will not proceed. Three directors have committed to subscribe for $75,000 in total under that tranche. Sonic's voting power would move from about 22.6% to about 24.5% after Tranche 1 and to about 26.0% after Tranche 2.

Cost reduction programme

Annualised cash operating costs have fallen by about $5 million, or more than 20%, compared with FY26. Q1 FY27 included about $0.45 million of one-off restructuring payments, and the full benefit is not yet reflected because some notice periods ran through the quarter. After slower-than-expected revenue growth in the United Kingdom, a further reduction of about $3 million is planned, taking the total to more than 30% of the FY26 cost base. The focus areas include property consolidation, a simpler leadership structure, a smaller board and lower contractor, marketing and software spending. An interim chief executive was appointed on 25 September, and two directors will retire as the board shrinks.

Quarterly trading

Core testing revenue was $2.57 million, up 31% on the prior corresponding period and the 13th consecutive quarter of core testing growth. Total revenue of $3.44 million was down 4% on the prior period, reflecting the exit of legacy and distributed products, and down 16% on the previous quarter, which included about $0.4 million of annual partner revenue. A laboratory delay in late September moved $0.21 million of revenue into October. Core test volume reached 6,527 tests, including 5,589 Australian Microbiome Explorer tests, up 44%. GI Navigator launched in Australia and the United Kingdom on 7 October 2026.

Cash position

Cash receipts were $4.27 million, and the net operating cash outflow was $3.80 million, or $3.01 million after normalising for restructuring and annual payments. Cash and equivalents were $3.87 million at 30 September 2026. Microba also plans an advisory process for a potential sale of its UK-based Invivo Supplements business.

Leadership and portfolio changes

Microba stated that the smaller board is consistent with the composition agreed for the combined group should the proposed merger with Genetic Signatures, announced on 22 September 2026, proceed. The quarterly report adds that new Australian pricing took effect on 1 September 2026, with list prices up 13% to 22%, that Microbiome Explorer deferred revenue was $1.99 million, up 54%, and that ordering clinicians rose 15% to 963.

Where the announcements leave the company

The releases pair a $2.025 million capital raising with lower operating costs, growth in core testing revenue, lower total revenue and a continuing net cash outflow, with the second tranche of the placement tied to the proposed Genetic Signatures merger.